losartan has been researched along with avapro in 211 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 34 (16.11) | 18.2507 |
| 2000's | 108 (51.18) | 29.6817 |
| 2010's | 54 (25.59) | 24.3611 |
| 2020's | 15 (7.11) | 2.80 |
| Authors | Studies |
|---|---|
| Assens, JL; Bernhart, CA; Clément, J; Ferrari, BP; Haudricourt, F; Muneaux, CF; Muneaux, YA; Perreaut, PM; Taillades, JE; Vignal, MA | 1 |
| Goldberg, MR; Greenlee, WJ; Irvin, JD; Prendergast, K; Smith, RD; Timmermans, PB; Wexler, RR | 1 |
| Abbenante, G; Fairlie, DP; Leung, D | 1 |
| Berellini, G; Cruciani, G; Mannhold, R | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Giridhar, R; Murumkar, P; Naik, P; Yadav, MR | 1 |
| Fukami, T; Hosomi, H; Iwamura, A; Nakajima, M; Yokoi, T | 1 |
| Barton, P; Luker, T; Wenlock, MC | 1 |
| Chen, ZL; Da, YJ; Jia, L; Liang, LS; Nie, YY; Tian, J; Wen, CH; Yang, XX; Zheng, H | 1 |
| Chen, ZL; Da, YJ; Liang, LS; Nie, YY; Xin, T; Yan, YJ; Ye, Y; Yuan, WD | 1 |
| Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Benachour, N; Vanderheyden, PML | 1 |
| Gust, R; Obexer, P; Salcher, S; Schoepf, AM | 1 |
| Foster, H; Foster, R; Philippou, H; Wilson, C | 1 |
| Norman, BH | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Cazaubon, C; Chatelain, P; Christophe, B; Libon, R; Manning, A; Nisato, D | 1 |
| Brunner, HR; Burnier, M; Nussberger, J; Pechère-Bertschi, A; Waeber, B | 1 |
| Canals, F; Cazaubon, C; Galindo, G; Lacour, C; Nisato, D; Segondy, D | 1 |
| Bauer, JH; Reams, GP | 1 |
| Cazaubon, C; Chatelain, P; Delisée, C; Dol, F; Herbert, JM; Nisato, D; Schaeffer, P | 1 |
| Cazaubon, C; Chatelain, P; Delisée, C; Schaeffer, P | 1 |
| Cazaubon, C; Lacour, C; Nisato, D; Roccon, A; Segondy, D | 1 |
| Velasquez, MT | 1 |
| Biollaz, J; Brunner, HR; Buclin, T; Burnier, M; Nussberger, J; Waeber, B | 1 |
| García-Sáinz, JA; González-Espinosa, C; Martínez-Alfaro, M; Romero-Avila, MT | 1 |
| Brooks, DP; Feuerstein, GZ; Ohlstein, EH; Ruffolo, RR | 1 |
| Adler, E; Elliott, W; Kassler-Taub, K; Littlejohn, T; Ruddy, T | 1 |
| Hällfritzsch, U; Schwarzbeck, A; Wittenmeier, KW | 1 |
| Cazaubon, C; Ciccocioppo, R; Massi, M; Nisato, D; Polidori, C | 1 |
| Pylypchuk, GB | 1 |
| Brown, MJ | 1 |
| Morsing, P | 1 |
| Bunt, T | 2 |
| Chung, O; Csikós, T; Unger, T | 1 |
| Culman, J; Piepenburg, B; Rascher, W; Unger, T; von Heyer, C | 1 |
| Brunner, HR; Burnier, M; Maillard, M; Mazzolai, L; Nussberger, J; Rossat, J | 1 |
| Baan, J | 1 |
| Abrahamsson, T; Adler, G; Brandt-Eliasson, U; Karp, L; Morsing, P; Ohlson, K; Renberg, L; Sjöquist, PO | 1 |
| Kirk, JK | 1 |
| De Backer, JP; Fierens, FL; Vanderheyden, PM; Vauquelin, G | 1 |
| Kaplan, NM | 1 |
| Belz, GG; Butzer, R; Kober, S; Mang, C; Mutschler, E | 1 |
| Spence, JD | 1 |
| Fluharty, SJ; Hines, J; Sakai, RR | 1 |
| Coca, A; Giner, V | 1 |
| Brunner, HR; Burnier, M; Centeno, C; Daven, V; Maillard, MP; Mazzolai, L; Nussberger, J | 1 |
| Cody, RJ; Goetze, S; Graf, K; Hsueh, WA; Kawano, H; Kawano, Y; Law, RE; Schnee, J | 1 |
| Petkun, W | 1 |
| Benedict, C; Bunt, AM; Conlin, PR; Ribeiro, AB; Saito, I; Spence, JD; Williams, B | 1 |
| Casado, S; Farré, J; Gómez, J; Jiménez, A; López-Blaya, A; López-Farré, A; Montón, M; Núñez, A; Sánchez de Miguel, L; Zalba, LR | 1 |
| DelGrande, D; Shetty, SS | 1 |
| Kiukaanniemi, K; Pelkonen, O; Taavitsainen, P | 1 |
| Grossman, E; Messerli, FH; Neutel, JM | 1 |
| Howes, L; Wong, W | 1 |
| Fierens, FL; Vanderheyden, PM; Vauquelin, G | 1 |
| Badguet, JP; Mallion, JM | 1 |
| Burnier, M | 1 |
| De Backer, JP; Fierens, FL; Morsing, P; Vanderheyden, PM; Vauquelin, G | 1 |
| Vidt, DG | 1 |
| Balt, JC; Mathy, MJ; Pfaffendorf, M; van Zwieten, PA | 1 |
| Ramahi, TM | 1 |
| Giatas, N; Golic Grdadolnik, S; Iliodromitis, EK; Keivish, T; Kremastinos, DT; Matsoukas, J; Mavromoustakos, T; Mutule, I; Polevaya, L; Roumelioti, P; Vlahakos, DV; Zoumboulakis, P | 1 |
| Balt, JC; Mathy, MJ; Nap, A; Pfaffendorf, M; van Zwieten, PA | 1 |
| Coats, AJ | 1 |
| Li, Q; Pfaffendorf, M; van Zwieten, PA | 1 |
| Alonso, RM; Cagigal, E; González, L; Jiménez, RM | 1 |
| Bloomgarden, ZT | 1 |
| Brunner, HR; Burnier, M; Chiolero, A; Fallab-Stubi, CL; Gerster, JC; Maillard, M; Würzner, G | 1 |
| Kurtzman, NA | 1 |
| Atkins, RC; Cooper, ME; Gilbert, RE; Jerums, G | 1 |
| Beevers, DG; Lip, GY | 1 |
| Christides, D; Elisaf, M; Liberopoulos, E | 1 |
| Brunner, HR; Burnier, M; Centeno, C; Maillard, MP; Nussberger, J; Würzner, G | 1 |
| Akesolo, U; Alonso, RM; González, L; Jiménez, RM | 1 |
| Walser, M | 1 |
| Ceriello, A; Motz, E | 1 |
| MacGregor, GA; Swift, PA | 1 |
| Howes, LG; Tran, D | 1 |
| Belz, GG; Breithaupt-Grögler, K; Butzer, R; Fuchs, W; Hausdorf, C; Mang, C | 1 |
| Doggrell, SA | 2 |
| Ganado, P; Sanz, M; Tejerina, T | 1 |
| Studney, D | 1 |
| Schiffrin, EL | 1 |
| Rapi, J | 1 |
| Hasford, J; Mimran, A; Simons, WR | 1 |
| Fakouhi, K; He, W; Krause, S; Krum, H; Nolly, H; Roniker, B; Workman, D | 1 |
| Ribeiro, AB; Zanella, MT | 1 |
| Balt, JC; Nap, A; Pfaffendorf, M; Van Zwieten, PA | 1 |
| Eguchi, K; Kario, K; Shimada, K | 1 |
| Suzuki, H | 2 |
| Allcock, NM; Graham, MR | 1 |
| Bassett, ML; Fisher, AA | 1 |
| Elmfeldt, D; Meredith, P; Olofsson, B | 1 |
| Karpov, IuA | 1 |
| Alvarez, A; Fernández-Calotti, P; Gamberale, R; Geffner, JR; Giordano, M; Nahmod, KA; Nahmod, V; Raiden, S; Salamone, G; Vermeulen, ME | 1 |
| Mancini, GB | 1 |
| Dikow, R; Eberhard, R | 1 |
| Beilin, LJ; Croft, KD; Proudfoot, JM; Puddey, IB | 1 |
| De Backer, JP; Vanderheyden, P; Vauquelin, G; Verheijen, I | 1 |
| Schieffer, B; Schmidt, B | 1 |
| Alföldi, S | 1 |
| Terra, SG | 1 |
| Bessard, G; Caron, F; Cracowski, JL; Hakim, A; Hoffmann, P; Sessa, C; Stanke-Labesque, F | 1 |
| Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV | 1 |
| de Jong-van den Berg, LT; de Zeeuw, D; Kruidhof, H; Postma, MJ | 1 |
| Jermendy, G; Matos, L; Winkler, G | 1 |
| Dominiak, P; Häuser, W | 1 |
| Arthur, S; Barrish, J; Baska, RA; Baumann, J; Beyer, S; Bird, E; Carlson, K; Dickinson, K; Fadnis, L; Ferrer, P; Giancarli, M; Gu, Z; Kane, B; Kowala, MC; Macor, JE; Monshizadegan, H; Murugesan, N; Panchal, B; Perrone, M; Ryan, C; Tellew, J; Trippodo, N; Yang, Y; Zhang, D | 1 |
| Ruilope, LM; Segura, J | 1 |
| Daliani, I; Dimitriou, D; Kamoutsis, C; Kyrikou, I; Laggner, P; Mavromoustakos, T; Pitsas, A; Siapi, E; Zervou, M; Zoga, A; Zoumpoulakis, P | 1 |
| Chambliss, ML; Foreman, BH | 1 |
| Avery, MA; Benson, SC; Chittiboyina, A; Desai, P; Ho, CI; Kurtz, TW; Pershadsingh, HA; Pravenec, M; Qi, N; Wang, J | 1 |
| Ivanova, NA; Preobrazhenskiĭ, DV; Sidorenko, BA; Soplevenko, AV; Stetsenko, TM | 1 |
| Clasen, R; Janke, J; Kintscher, U; Schupp, M; Unger, T | 1 |
| Ahn, JY; Ahn, TH; Chung, WJ; Han, SH; Jin, DK; Kang, WC; Kim, HS; Koh, KK; Park, GS; Shin, EK | 1 |
| Stumpe, KO | 1 |
| Dubiel, R; Jones, M; Smith, DH | 1 |
| Isreb, MA; Leehey, DJ; Marcic, S; Singh, AK; Singh, R | 1 |
| Shlipak, M | 1 |
| Dendorfer, A; Dominiak, P; Raasch, W; Tempel, K | 1 |
| Chen, G; Dang, A; Liu, G; Song, W; Wang, B; Zhang, Y | 1 |
| Pershadsingh, HA | 1 |
| Feng, YQ; Nie, J; Wei, F; Zhang, M; Zhang, YF | 1 |
| Fontanazza, A; Martarelli, D; Pediconi, D; Pompei, P | 1 |
| Burnier, M; Zanchi, A | 1 |
| Sica, DA | 1 |
| Gavras, H; Ribeiro, AB | 1 |
| Bianchetti, MG; Fossali, E; Konrad, M; Rizzi, M; Simonetti, GD; von Vigier, RO | 1 |
| Boschmann, M; Engeli, S; Gorzelniak, K; Janke, J; Jordan, J; Luft, FC; Nystrom, FH; Sauma, L; Schupp, M; Sharma, AM | 1 |
| Bandlow, N; Beck, S; Drexler, H; Grote, K; Kaszkin, M; Luchtefeld, M; Pfeilschifter, J; Schieffer, B; Tietge, UJ | 1 |
| Al-Hiari, YM; Alhamami, OM; Shakya, AK | 1 |
| Chen, GL; Dang, AM; Liu, GZ; Zhang, YH | 1 |
| Bianchetti, MG; Fossali, E; Ghiglia, S; Limoni, C; Meier, CM; Salice, P; Simonetti, GD | 1 |
| Behlouli, H; Hudson, M; Humphries, K; Pilote, L; Sheppard, R; Tu, JV | 1 |
| Belsey, JD | 1 |
| Brooke, BS; Dietz, HC; Habashi, JP; Judge, DP; Loeys, B; Patel, N | 1 |
| Dal Pan, GJ; Governale, LA; Hammad, TA; McAdams, MA; Swartz, L | 1 |
| Hatzitolios, A; Ntaios, G; Savopoulos, C | 1 |
| Grigg, M; Harahap, Y; Lusthom, W; Prasaja, B; Sasongko, L | 1 |
| Bae, SK; Cho, DY; Kim, EY; Kim, MJ; Liu, KH; Shim, EJ; Shin, JG; Shon, JH | 1 |
| Falvey, H; Lowy, A; Müller, E; Nixon, RM | 1 |
| Cerar, LK; Cvijic, M; Gersak, K | 1 |
| Ji, HY; Lee, HS; Lee, HW; Lee, KC; Park, ES | 1 |
| Alfarano, C; Cerbai, E; Failli, P; Franchi-Micheli, S; Mannucci, E; Mugelli, A; Raimondi, L | 1 |
| Bähr, IN; Fleck, E; Fritzsche, J; Goebel, M; Gust, R; Hässle, PL; Kappert, K; Kaufmann, J; Kintscher, U; Ott, I; Stawowy, P; Tsuprykov, O; Unger, T | 1 |
| Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J | 1 |
| Kamiyama, E; Mikkaichi, T; Nakai, D; Okazaki, O; Okudaira, N | 1 |
| Bramlage, P; Schindler, C | 1 |
| Burnier, M; Coltamai, L; Maillard, M; Simon, A; Vogt, B | 1 |
| Fox, DA; Kashihara, N; Morita, Y; Sakuta, T; Satoh, M | 1 |
| Benndorf, RA; Böger, RH; Divac, N; Haefeli, WE; Herzog, M; Sauer, A; Schwedhelm, E; Weiss, J | 1 |
| Ekman, M; Fragoulakis, V; Maniadakis, N; Papagiannopoulou, V; Yfantopoulos, J | 1 |
| Arsenault, J; Cabana, J; Escher, E; Guillemette, G; Lanthier, L; Lavigne, P; Leduc, R; Lehoux, J | 1 |
| Fujino, M; Karnik, SS; Kiya, Y; Matsuo, Y; Miura, S; Saku, K; Tominaga, Y | 1 |
| Berl, T; de Graeff, PA; de Zeeuw, D; Holtkamp, FA; Lambers Heerspink, HJ; Laverman, GD; Lewis, JB; Packham, D; Parving, HH; Remuzzi, G | 1 |
| Horiuchi, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Oshima, K; Tsukuda, K | 1 |
| Circelli, M; Cremonesi, G; Fogari, R; Mugellini, A | 1 |
| Aparasu, RR; Ashton, CM; Chen, H; Desai, RJ; Deswal, A; Johnson, ML; Mehta, HB; Morgan, RO | 1 |
| Biskupiak, J; Qian, C; Quah, R; Ram, CV; Ramaswamy, K; Russo, PA; Ryan, A | 1 |
| Bakker, SJ; Berl, T; Cooper, ME; de Zeeuw, D; Lambers Heerspink, HJ; Laverman, GD; Smink, PA | 1 |
| Joffe, MM; Yang, W | 1 |
| Kusunoki, H; Morishita, R; Rakugi, H; Taniyama, Y | 1 |
| Inamdar, MN; Kulkarni, C; Kulkarni, KS; Moinuddin, G | 1 |
| Antoniou, T; Camacho, X; Gomes, T; Juurlink, DN; Mamdani, MM; Yao, Z | 1 |
| Bigagli, E; Lodovici, M; Manni, ME; Musilli, C; Raimondi, L; Zazzeri, M | 1 |
| Allen, RR; Ghushchyan, V; Kaila, S; Nair, KV; Saseen, JJ | 1 |
| Coresh, J; de Zeeuw, D; Dwyer, JP; Gansevoort, R; Greene, T; Inker, LA; Lambers Heerspink, HJ; Levey, AS; Mondal, H; Parving, HH; Weldegiorgis, M | 1 |
| Caffrey, JL; Chang, CH; Lai, MS; Lin, JW; Wu, LC | 1 |
| Addabbo, F; Carratù, MR; Iacobazzi, D; Leo, V; Montagnani, M; Potenza, MA; Sgarra, L | 1 |
| Bakker, SJ; Cooper, ME; de Zeeuw, D; Deetman, PE; Lambers Heerspink, HJ; Lewis, JB; Navis, G; Riphagen, IJ | 1 |
| Agarwal, A; Hull, TD | 1 |
| Dong, Z; Ekins, S; Polli, JE | 1 |
| de Zeeuw, D; Lambers Heerspink, HJ; Parving, HH; Rossing, P; Schievink, B | 1 |
| Bakker, SJ; de Zeeuw, D; Gansevoort, RT; Lambers Heerspink, HJ; Lewis, JB; Lutgers, HL; Schutte, E; Umanath, K; Vart, P; Wolffenbuttel, BH | 1 |
| Deng, SB; Du, JL; Liu, YJ; Qiu, B; She, Q; Wang, J | 1 |
| Brown, SA; Coleman, AE; Jenkins, TL; Schmiedt, CW | 1 |
| de Zeeuw, D; Felix Kröpelin, T; Holtkamp, FA; L Heerspink, HJ; Packham, DK | 1 |
| Anzai, N; Hamada, T; Hirota, Y; Hisatome, I; Ikeda, N; Kato, M; Kuwabara, M; Maharani, N; Mishima, M; Miyazaki, S; Mizuta, E; Ninomiya, H; Notsu, T; Ogino, K; Onohara, T; Otani, N; Sugihara, S; Yoshida, A | 1 |
| Asayama, K; Haga, T; Hosaka, M; Imai, Y; Inoue, R; Kikuya, M; Mano, N; Metoki, H; Murakami, T; Obara, T; Ohkubo, T; Satoh, M | 1 |
| Ah, YM; Choi, KH; Choi, YJ; Han, N; Kim, B; Kong, J; Lee, HY; Lee, JY; Oh, JM; Shin, WG; Yu, YM | 1 |
| Andersen, S; Dallmann, G; Heerspink, HJ; Heinzel, A; Mayer, B; Parving, HH; Pena, MJ; Rossing, K; Rossing, P | 1 |
| Agbaba, D; Grujić, M; Nikolic, K; Popović, G; Popović, M | 1 |
| Caltagirone, C; Cooper, GJ; Crisponi, G; Jaraquemada-Pelaez, MG; Lachowicz, JI; Nurchi, VM; Peana, M; Szewczuk, Z; Zoroddu, MA | 1 |
| Brolund, L; Brolund-Spaether, K; Cascorbi, I; Culman, J; Gohlke, P; Jacob, T; Schuster, SO; Zhao, Y | 1 |
| Guo, CX; Li, X; Liu, JY; Liu, SK; Liu, ZQ; Luo, M; Pei, Q; Xie, P; Yang, GP; Yin, JY; Zheng, Y; Zhou, HH | 1 |
| Jóźwiak, K; Kocki, T; Targowska-Duda, KM; Turski, WA; Wnorowski, A; Zakrocka, I | 1 |
| Bhalla, V; Byrd, JB; Chertow, GM | 1 |
| Abdelsalam, RA; Haddad, GM; Marghany, KA | 1 |
| Aboul-Enein, HY; Ali, I; ALOthman, ZA; Alsheetan, KM | 1 |
| Kim, H; Kim, HS; Kim, JH; Lee, SH | 1 |
| Chountoulesi, M; Demetzos, C; Mavromoustakos, T; Naziris, N; Ntountaniotis, D | 1 |
| Daugherty, A; Franklin, MK; Howatt, DA; Lu, HS; Moorleghen, JJ; Mullick, AE; Ohno-Urabe, S; Sawada, H; Ye, D | 1 |
| Bester, K; Kisielius, V; Li, R; Liang, C; Svendsen, SB | 1 |
| Dantas, ASCL; de Lima, PC; de Souza, MN; Ferreira, LODS; Lima, MED; Maranho, RLDN; Monteiro, MA; Novotny, TS; Ochs, SM; Santana, DS | 1 |
| Bradley, MC; Eworuke, E; Ghosh, RE; Hou, L; Jensen, PB; Lee, H; Maro, JC; Paterson, MJ; Pennap, D; Platt, RW; Pottegard, A; Rai, A; Scarnecchia, D; Shinde, M; Welburn, S; Woronow, D | 1 |
| Bradley, M; Eworuke, E; Hedenmalm, K; Kurz, X; Lee, H; Quinten, C | 1 |
| Liang, H; Tang, T; Xie, M | 1 |
| Jeong, HE; Kim, JS; Ko, H; Lim, MJ; Shin, JY; Yoo, YG | 1 |
60 review(s) available for losartan and avapro
| Article | Year |
|---|---|
Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Humans; Receptors, Angiotensin; Structure-Activity Relationship | 1996 |
Protease inhibitors: current status and future prospects.
Topics: Animals; Aspartic Acid Endopeptidases; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Humans; Metalloendopeptidases; Models, Molecular; Protease Inhibitors; Serine Endopeptidases; Serine Proteinase Inhibitors | 2000 |
Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Losartan | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Influence of the cellular environment on ligand binding kinetics at membrane-bound targets.
Topics: Angiotensin II Type 1 Receptor Blockers; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Kinetics; Ligands; Protein Binding; Receptor, Angiotensin, Type 1; Receptors, Cell Surface; Signal Transduction | 2017 |
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
Topics: Animals; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Drug Discovery; Drug Evaluation, Preclinical; Hepatocytes; Humans; Liver; Mitochondria, Liver; Pharmaceutical Preparations; Risk Assessment; Tissue Distribution | 2020 |
The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs.
Topics: Acrylates; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Humans; Imidazoles; Irbesartan; Losartan; Pyridines; Quinolines; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 1995 |
Angiotensin II receptor blockers. A new class of antihypertensive drugs.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzothiadiazines; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Diuretics; Enalapril; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Multicenter Studies as Topic; Rats; Rats, Inbred SHR; Renin-Angiotensin System; Sodium Chloride Symporter Inhibitors; Tetrazoles | 1996 |
Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Imidazoles; Irbesartan; Losartan; Prodrugs; Reference Values; Tetrazoles | 1996 |
ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema.
Topics: Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Cough; Humans; Irbesartan; Losartan; Tetrazoles | 1998 |
Irbesartan treatment in hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Enalapril; Humans; Hypertension; Irbesartan; Losartan; Renin-Angiotensin System; Tetrazoles | 1998 |
Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Hemodynamics; Humans; Hypertension; Irbesartan; Kidney; Losartan; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles | 1999 |
Angiotensin II receptor pharmacology and AT1-receptor blockers.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Thiophenes | 1999 |
Angiotensin-II receptor antagonists: their place in therapy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Drug Administration Schedule; Drug Interactions; Heart Failure; Humans; Hypertension; Irbesartan; Losartan; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan | 1999 |
Angiotensin II receptor antagonists in the treatment of hypertension.
Topics: Algorithms; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Humans; Hypertension; Irbesartan; Losartan; Receptors, Angiotensin; Telmisartan; Tetrazoles; Valine; Valsartan | 1999 |
[Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Heart Diseases; Heart Failure; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 1999 |
Angiotensin II antagonists for hypertension: are there differences in efficacy?
Topics: Angiotensin II; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Humans; Hypertension; Irbesartan; Losartan; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2000 |
Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?
Topics: Acrylates; Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Drug Therapy, Combination; Heart; Humans; Hypertension; Imidazoles; Irbesartan; Kidney; Losartan; Renin-Angiotensin System; Telmisartan; Tetrazoles; Thiophenes | 2000 |
Angiotensin receptor antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Humans; Hypertension; Irbesartan; Losartan; Telmisartan; Tetrazoles | 2000 |
Putting the efficacy of candesartan cilexetil into perspective: a review of new comparative data.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cattle; Cerebellum; Circadian Rhythm; Female; Heart; Humans; Hypertension; In Vitro Techniques; Irbesartan; Kinetics; Losartan; Male; Middle Aged; Prodrugs; Rabbits; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Renin; Tetrazoles; Time Factors | 2000 |
Angiotensin II type 1 receptor blockers.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Binding, Competitive; Biphenyl Compounds; Blood Pressure; Drug Design; Humans; Irbesartan; Losartan; Peptidyl-Dipeptidase A; Protein Binding; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin-Angiotensin System; Saralasin; Tetrazoles; Valine; Valsartan | 2001 |
Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biological Availability; Biphenyl Compounds; Cardiovascular Diseases; Humans; Imidazoles; Irbesartan; Kidney Diseases; Losartan; Metabolic Clearance Rate; Patient Selection; Renin-Angiotensin System; Telmisartan; Tetrazoles; Thiophenes; Treatment Outcome; Valine; Valsartan | 2001 |
Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Humans; Hypertension; Irbesartan; Kidney Failure, Chronic; Losartan; Tetrazoles; Valine; Valsartan | 2001 |
The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy.
Topics: Aged; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Irbesartan; Losartan; Male; Middle Aged; Primary Prevention; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Sensitivity and Specificity; Tetrazoles; Treatment Outcome | 2001 |
Renoprotection in Type 2 diabetes: blockade of the renin-angiotensin system with angiotensin II receptor blockers.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Humans; Irbesartan; Kidney; Losartan; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Tetrazoles | 2001 |
Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema?
Topics: Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Humans; Irbesartan; Losartan; Telmisartan; Tetrazoles | 2002 |
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Calcium Channel Blockers; Captopril; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nephropathies; Humans; Irbesartan; Kidney Diseases; Losartan; Prognosis; Ramipril; Tetrazoles | 2002 |
Vascular changes in hypertension in response to drug treatment: Effects of angiotensin receptor blockers.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arteries; Atenolol; Biphenyl Compounds; Cilazapril; Humans; Hypertension; Irbesartan; Losartan; Perindopril; Tetrazoles | 2002 |
[Irbesartan: a new possibility in the treatment of hypertension].
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Benzimidazoles; Benzoates; Biological Availability; Biphenyl Compounds; Controlled Clinical Trials as Topic; Drug Administration Schedule; Enalapril; Half-Life; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2002 |
The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Irbesartan; Kidney Failure, Chronic; Losartan; Proteinuria; Renal Circulation; Tetrazoles | 2002 |
[What is a good marker for better antihypertensive therapy in diabetic patients when coexisting with hypertension].
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Captopril; Cardiomegaly; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetic Retinopathy; Humans; Hypertension; Irbesartan; Kidney Diseases; Losartan; Practice Guidelines as Topic; Risk; Tetrazoles | 2002 |
[Large scale clinical trials in prevention of end-stage renal disease due to type 2 diabetes with angiotensin receptor antagonists].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Irbesartan; Kidney Failure, Chronic; Losartan; Male; Middle Aged; Randomized Controlled Trials as Topic; Tetrazoles | 2002 |
[Evidence for the benefits of ACE inhibitors and AII antagonists in slowing progressive renal failure in diabetes].
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Captopril; Clinical Trials as Topic; Disease Progression; Humans; Irbesartan; Kidney Failure, Chronic; Losartan; Tetrazoles; Treatment Outcome | 2002 |
Acute pancreatitis associated with angiotensin II receptor antagonists.
Topics: Acute Disease; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diuretics; Drug Combinations; Female; Humans; Hydrochlorothiazide; Irbesartan; Losartan; Pancreatitis; Sodium Chloride Symporter Inhibitors; Tetrazoles | 2002 |
The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Irbesartan; Losartan; Male; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
[Clinical hypertensiology: analysis of trials completed in 2001-2002].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Cardiovascular Diseases; Diabetes Complications; Diastole; Diuretics; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Irbesartan; Losartan; Male; Middle Aged; Placebos; Randomized Controlled Trials as Topic; Risk; Risk Factors; Stroke; Systole; Tetrazoles; Time Factors | 2002 |
Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation.
Topics: Acrylates; Aged; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Coronary Artery Disease; Data Interpretation, Statistical; Diabetes Mellitus; E-Selectin; Endothelium, Vascular; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Tetrazoles; Thiophenes; Vasculitis | 2002 |
Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypertension, Renal; Irbesartan; Losartan; Renin-Angiotensin System; Tetrazoles | 2002 |
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Growth Hormone; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Models, Molecular; Receptor, Angiotensin, Type 1; Tetrazoles; Thiophenes; Thromboxane A2 | 2003 |
[Diurnal blood pressure control in the optimal treatment of hypertension].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Circadian Rhythm; Humans; Hypertension; Irbesartan; Losartan; Telmisartan; Tetrazoles; Valine; Valsartan | 2003 |
[Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diastole; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Irbesartan; Losartan; Meta-Analysis as Topic; Placebos; Prognosis; Randomized Controlled Trials as Topic; Sodium Chloride Symporter Inhibitors; Systole; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2003 |
Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Health Care Costs; Humans; Irbesartan; Kidney Failure, Chronic; Losartan; Tetrazoles; Treatment Outcome | 2003 |
[Theoretical background of angiotensin II receptor blockade and its features in clinical pharmacology].
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Humans; Imidazoles; Irbesartan; Losartan; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2003 |
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Topics: Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Irbesartan; Kidney Failure, Chronic; Losartan; Proteinuria; Tetrazoles | 2003 |
Efforts to understand the molecular basis of hypertension through drug:membrane interactions.
Topics: Amino Acids; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Binding Sites; Biphenyl Compounds; Calorimetry, Differential Scanning; Cell Membrane; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Magnetic Resonance Spectroscopy; Models, Molecular; Receptor, Angiotensin, Type 1; Tetrazoles; X-Ray Diffraction | 2004 |
Clinical inquiries. Are ARBs or ACE inhibitors preferred for nephropathy in diabetes?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Humans; Irbesartan; Losartan; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Tetrazoles | 2004 |
[Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetic Nephropathies; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2004 |
Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Editorial overview: The 'sartans': is it premature to consider PPARgamma receptor agonism a bonus?
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypertension; Irbesartan; Losartan; PPAR gamma; Rats; Rats, Zucker; Telmisartan; Tetrazoles | 2005 |
Diabetic nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Glucose; Captopril; Diabetic Nephropathies; Humans; Irbesartan; Losartan; Tetrazoles | 2004 |
Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Irbesartan; Losartan; Metabolic Syndrome; PPAR gamma; Telmisartan; Tetrazoles | 2006 |
Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Disease Progression; Humans; Hypertension; Irbesartan; Losartan; Renin-Angiotensin System; Tetrazoles | 2006 |
Angiotensin receptor blockers: new considerations in their mechanism of action.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Hemodynamics; Humans; Irbesartan; Losartan; Sympathetic Nervous System; Tetrazoles | 2006 |
Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular System; Diabetic Nephropathies; Humans; Hypertension; Irbesartan; Kidney; Losartan; Proteinuria; Tetrazoles | 2006 |
Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Dose-Response Relationship, Drug; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Middle Aged; Prospective Studies; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan.
Topics: Administration, Oral; Angiotensin II; Antihypertensive Agents; Biological Availability; Biphenyl Compounds; Blood Pressure; Diabetic Nephropathies; Health Care Costs; Humans; Hypertension; Irbesartan; Losartan; Tetrazoles; Treatment Outcome | 2010 |
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biphenyl Compounds; Case-Control Studies; Double-Blind Method; Humans; Hypertension; Irbesartan; Losartan; Neoplasms; Randomized Controlled Trials as Topic; Telmisartan; Tetrazoles | 2011 |
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Calcium Channel Blockers; Cardiotonic Agents; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Female; Heart Failure; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Stroke; Tetrazoles; Treatment Outcome | 2011 |
Combination delapril/manidipine as antihypertensive therapy in high-risk patients.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Diabetes Complications; Dihydropyridines; Drug Combinations; Enalapril; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Indans; Irbesartan; Losartan; Nitrobenzenes; Obesity; Olmesartan Medoxomil; Piperazines; Ramipril; Tetrazoles; Valine; Valsartan | 2011 |
Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Essential Hypertension; Humans; Hydrochlorothiazide; Hypertension; Irbesartan; Losartan; Network Meta-Analysis; Telmisartan; Tetrazoles; Valine; Valsartan | 2023 |
24 trial(s) available for losartan and avapro
| Article | Year |
|---|---|
Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators.
Topics: Adolescent; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Female; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Tetrazoles; Treatment Outcome | 1998 |
Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cross-Over Studies; Double-Blind Method; Humans; Irbesartan; Losartan; Male; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Time Factors; Valine; Valsartan | 1999 |
Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay.
Topics: Adult; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Chromatography, High Pressure Liquid; Confounding Factors, Epidemiologic; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Half-Life; Humans; Irbesartan; Losartan; Male; Radioligand Assay; Reference Values; Tetrazoles; Time Factors; Valine; Valsartan | 1999 |
Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biomarkers; Biphenyl Compounds; Blood Pressure; Cross-Over Studies; Double-Blind Method; Humans; Hypertension; Irbesartan; Losartan; Radioligand Assay; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Reproducibility of Results; Tetrazoles; Valine; Valsartan; Vasoconstrictor Agents | 1999 |
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Chronic Disease; Cross-Over Studies; Double-Blind Method; Gout; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Prospective Studies; Tetrazoles; Uric Acid | 2001 |
Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cross-Over Studies; Dose-Response Relationship, Drug; Humans; Irbesartan; Losartan; Male; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2002 |
The pharmacological potency of various AT(1) antagonists assessed by Schild regression technique in man.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Irbesartan; Losartan; Male; Receptor, Angiotensin, Type 1; Reference Values; Tetrazoles; Valine; Valsartan | 2000 |
Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Eplerenone; Female; Headache; Heart Rate; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Patient Dropouts; Renin-Angiotensin System; Spironolactone; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension.
Topics: Angiotensin II; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Brachial Artery; Double-Blind Method; Female; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Tetrazoles; Vasodilation | 2004 |
Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Double-Blind Method; Female; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Monitoring, Physiologic; Olmesartan Medoxomil; Single-Blind Method; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2005 |
Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population.
Topics: Angiotensin II Type 1 Receptor Blockers; Asian People; Biphenyl Compounds; Blood Pressure; China; Double-Blind Method; Female; Humans; Hypertension; Hyperuricemia; Incidence; Irbesartan; Losartan; Male; Middle Aged; Tetrazoles; Treatment Outcome; Uric Acid | 2006 |
Candesartan cilexetil in children with hypertension or proteinuria: preliminary data.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Child; Child, Preschool; Female; Humans; Hypertension; Infant; Irbesartan; Losartan; Male; Proteinuria; Tablets; Tetrazoles | 2006 |
Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Biphenyl Compounds; Cells, Cultured; Coronary Artery Disease; Enzyme Activation; Enzyme Inhibitors; Female; Group II Phospholipases A2; Humans; Hypertension; Indoles; Irbesartan; Lipid Peroxidation; Lipoproteins, LDL; Losartan; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; RNA, Messenger; Tetrazoles | 2007 |
[The effects of angiotensin II receptor blockers in hypertensive patients complicating hyperuricaemia].
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Tetrazoles; Uric Acid | 2006 |
Palatability of angiotensin II antagonists among nephropathic children.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Child; Child, Preschool; Female; Humans; Irbesartan; Kidney Diseases; Losartan; Male; Patient Compliance; Patient Satisfaction; Smell; Taste; Telmisartan; Tetrazoles; Valine; Valsartan | 2007 |
Angiotensin II blockade and aortic-root dilation in Marfan's syndrome.
Topics: Adolescent; Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aorta; Biphenyl Compounds; Blood Pressure; Calcium Channel Blockers; Child; Child, Preschool; Drug Therapy, Combination; Female; Heart Rate; Humans; Infant; Irbesartan; Linear Models; Losartan; Male; Marfan Syndrome; Prospective Studies; Tetrazoles; Transforming Growth Factor beta | 2008 |
Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Cell Movement; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Muscle Cells; PPAR gamma; Telmisartan; Tetrazoles | 2009 |
Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Imidazoles; Irbesartan; Kidney Tubules; Losartan; Single-Blind Method; Tetrazoles; Valine; Valsartan | 2010 |
An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular System; Data Interpretation, Statistical; Diabetic Nephropathies; Female; Humans; Irbesartan; Losartan; Male; Middle Aged; Placebos; Proportional Hazards Models; Risk; Risk Factors; Tetrazoles; Treatment Outcome; Uric Acid | 2012 |
Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Irbesartan; Kidney Failure, Chronic; Losartan; Male; Middle Aged; Tetrazoles | 2014 |
The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Blood Pressure; Cholesterol; Creatinine; Diabetes Mellitus, Type 2; Female; Hemoglobins; Humans; Individuality; Irbesartan; Kidney; Kidney Failure, Chronic; Losartan; Male; Middle Aged; Potassium; Prospective Studies; Risk Factors; Tetrazoles; Uric Acid | 2015 |
Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Bicarbonates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Disease Progression; Female; Humans; Irbesartan; Kidney Failure, Chronic; Losartan; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Factors; Tetrazoles | 2015 |
The effects of a low-salt diet on the efficacy of different antihypertensive drug regimens.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diet, Sodium-Restricted; Drug Synergism; Drug Therapy, Combination; Essential Hypertension; Female; Humans; Hydrochlorothiazide; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Tetrazoles; Young Adult | 2015 |
Attenuation of the pressor response to exogenous angiotensin by angiotensin receptor blockers and benazepril hydrochloride in clinically normal cats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Cats; Cross-Over Studies; Irbesartan; Losartan; Telmisartan; Tetrazoles | 2015 |
127 other study(ies) available for losartan and avapro
| Article | Year |
|---|---|
A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Female; Imidazoles; In Vitro Techniques; Irbesartan; Macaca fascicularis; Male; Rabbits; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Sensitivity and Specificity; Structure-Activity Relationship; Tetrazoles | 1993 |
Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Binding Sites; Biphenyl Compounds; Kinetics; Losartan; Models, Molecular; Molecular Conformation; Oxidation-Reduction; Pharmaceutical Preparations; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Structure-Activity Relationship; Tetrazoles | 2005 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Topics: Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Benzbromarone; Biotransformation; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; Diclofenac; HEK293 Cells; Hep G2 Cells; Hepatocytes; Humans; Losartan; NF-E2-Related Factor 2; Semicarbazides; Sensitivity and Specificity; Time Factors; Uricosuric Agents | 2011 |
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
Topics: Acids; Albumins; Drug Design; Humans; Hydrogen-Ion Concentration; Lipids; Molecular Structure; Pharmaceutical Preparations; Protein Binding | 2011 |
Synthesis and biological evaluation of novel potent angiotensin II receptor antagonists with anti-hypertension effect.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Cells, Cultured; Dose-Response Relationship, Drug; Molecular Conformation; Molecular Structure; Rats; Rats, Inbred SHR | 2012 |
Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Antineoplastic Agents; Cell Line, Tumor; Humans; Hydrocarbons, Fluorinated; Hypertension; Male; Mice; Mice, Nude; Prostatic Neoplasms; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2012 |
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
Topics: Animals; Cell Death; Cell Proliferation; Chlorocebus aethiops; COS Cells; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; PPAR gamma; Structure-Activity Relationship; Telmisartan | 2020 |
Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
Topics: Binding Sites; Biological Products; Humans; Ligands; Losartan; Molecular Dynamics Simulation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Signal Transduction; Small Molecule Libraries; Thrombosis | 2020 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Effects of irbesartan (SR47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: potential mechanisms of action.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Imidazoles; Irbesartan; Losartan; Male; Rats; Rats, Wistar; Receptors, Angiotensin; Tetrazoles; Time Factors | 1995 |
Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive systems.
Topics: Adult; Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Humans; Imidazoles; Irbesartan; Kidney; Kidney Tubules; Losartan; Natriuresis; Potassium; Renin-Angiotensin System; Sodium; Sodium, Dietary; Tetrazoles; Uric Acid; Vasomotor System; Water | 1995 |
Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Desoxycorticosterone; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Tolerance; Enalapril; Hypertension, Renal; Imidazoles; Injections, Intravenous; Irbesartan; Losartan; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Sprague-Dawley; Renin; Renin-Angiotensin System; Tachycardia; Tetrazoles | 1994 |
Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Calcium; Cell Division; Cells, Cultured; Humans; Imidazoles; Iodine Radioisotopes; Irbesartan; Losartan; Mitogens; Muscle, Smooth, Vascular; Protein Binding; Tetrazoles | 1994 |
Characterization of cardiac angiotensin AT1 receptors by [3H]SR 47436.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Biphenyl Compounds; Calcium; Cells, Cultured; Heart; Homeostasis; Imidazoles; Irbesartan; Kinetics; Losartan; Myocardium; Pyridines; Rats; Rats, Wistar; Receptors, Angiotensin; Tetrazoles | 1993 |
Pharmacological study of SR 47436, a non-peptide angiotensin II AT1-receptor antagonist, in conscious monkeys.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Female; Imidazoles; Irbesartan; Losartan; Macaca fascicularis; Male; Renin; Sodium, Dietary; Tetrazoles | 1993 |
Characterization of the AT1 angiotensin II receptor expressed in guinea pig liver.
Topics: Angiotensin I; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Binding, Competitive; Biphenyl Compounds; Enzyme Activation; Guinea Pigs; Imidazoles; Irbesartan; Liver; Losartan; Male; Polymerase Chain Reaction; Pyridines; Receptors, Angiotensin; RNA, Messenger; Tetrazoles | 1997 |
Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Decerebrate State; Electric Stimulation; Imidazoles; Irbesartan; Losartan; Male; Rats; Rats, Sprague-Dawley; Sympathetic Nervous System; Tetrazoles; Thiophenes; Valine; Valsartan | 1997 |
Anaemia in dialysis patients as a side-effect of sartanes.
Topics: Anemia; Antihypertensive Agents; Biphenyl Compounds; Hemoglobins; Humans; Irbesartan; Kidney Transplantation; Losartan; Renal Dialysis; Renal Insufficiency; Retrospective Studies; Tetrazoles | 1998 |
Evaluation of the ability of irbesartan to cross the blood-brain barrier following acute intragastric treatment.
Topics: Adrenalectomy; Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood-Brain Barrier; Carbachol; Drug Evaluation; Injections, Intraventricular; Irbesartan; Losartan; Male; Rats; Rats, Inbred SHR; Rats, Wistar; Stomach; Tetrazoles | 1998 |
Problems with interpreting the data in Kassler-Taub et al's article comparing irbesartan and losartan.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Decision Making; Drug Labeling; Follow-Up Studies; Humans; Hypertension; Irbesartan; Losartan; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 2; Tetrazoles; United States; United States Food and Drug Administration | 1999 |
Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats.
Topics: Administration, Oral; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Brain; Dose-Response Relationship, Drug; Drinking; Drug Interactions; Injections, Intravenous; Injections, Intraventricular; Irbesartan; Losartan; Male; Pituitary Gland, Posterior; Rats; Rats, Wistar; Tetrazoles; Vasopressins | 1999 |
An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Humans; Hypertension; Irbesartan; Losartan; Tetrazoles; Titrimetry | 1999 |
AT1-receptor antagonists for the treatment of chronic heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biphenyl Compounds; Captopril; Dogs; Heart Failure; Humans; Irbesartan; Losartan; Rats; Tetrazoles | 1999 |
Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood Proteins; Female; Humans; Imidazoles; In Vitro Techniques; Irbesartan; Kinetics; Losartan; Male; Muscle Contraction; Muscle, Smooth, Vascular; Portal Vein; Rabbits; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles | 1999 |
Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Binding, Competitive; Biphenyl Compounds; CHO Cells; Cricetinae; Dose-Response Relationship, Drug; Humans; Imidazoles; Irbesartan; Losartan; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Recombinant Proteins; Tetrazoles | 1999 |
Efficacy of angiotensin II antagonists in hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diuretics; Drug Interactions; Drug Therapy, Combination; Humans; Hypertension; Irbesartan; Losartan; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1999 |
The angiotensin AT(1) receptor antagonist irbesartan has near-peptide affinity and potently blocks receptor signaling.
Topics: Adrenal Glands; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Binding, Competitive; Biphenyl Compounds; Cells, Cultured; Dose-Response Relationship, Drug; Iodine Radioisotopes; Irbesartan; Kidney; Liver; Losartan; Male; PC12 Cells; Pituitary Gland; Pyrimidines; Radioligand Assay; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Signal Transduction; Tetrazoles | 1999 |
Angiotensin II enhances integrin and alpha-actinin expression in adult rat cardiac fibroblasts.
Topics: Actinin; Age Factors; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antigens, CD; Antihypertensive Agents; Biphenyl Compounds; Cardiomegaly; Cell Adhesion; Cell Adhesion Molecules; Cells, Cultured; Collagen; Fibroblasts; Fibronectins; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression; Heart Ventricles; Hydralazine; Imidazoles; Integrin alphaV; Integrin beta Chains; Integrin beta1; Integrin beta3; Integrins; Irbesartan; Laminin; Losartan; Myocardium; Phosphorylation; Platelet Membrane Glycoproteins; Protein-Tyrosine Kinases; Pyridines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; RNA, Messenger; Tetrazoles; Up-Regulation; Vitronectin | 2000 |
AT1-receptor blockers.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Heart Failure; Humans; Hypertension; Irbesartan; Losartan; Meta-Analysis as Topic; Tetrazoles; Valine; Valsartan | 2000 |
Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antibodies, Monoclonal; Benzimidazoles; Benzoates; Binding, Competitive; Biphenyl Compounds; Blood Platelets; Dose-Response Relationship, Drug; Humans; Imidazoles; Irbesartan; Losartan; Platelet Activation; Pyridines; Radioligand Assay; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Telmisartan; Tetrazoles; Thromboxane A2; Time Factors; Valine; Valsartan | 2000 |
Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Dose-Response Relationship, Drug; Heart; Imidazoles; Irbesartan; Losartan; Male; Norepinephrine; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha; Receptors, Angiotensin; Sympathetic Nervous System; Tetrazoles; Thiophenes; Valine; Valsartan | 2000 |
In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists.
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Imidazoles; In Vitro Techniques; Inhibitory Concentration 50; Irbesartan; Losartan; Microsomes, Liver; Protein Isoforms; Tetrazoles; Thiophenes; Valine; Valsartan | 2000 |
Angiotensin II type 1 receptor antagonists. Why do some of them produce insurmountable inhibition?
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Binding Sites; Biphenyl Compounds; CHO Cells; Cricetinae; Dose-Response Relationship, Drug; Humans; Irbesartan; Losartan; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Recombinant Proteins; Tetrazoles | 2000 |
A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; CHO Cells; Computer Simulation; Cricetinae; Dose-Response Relationship, Drug; Inositol Phosphates; Irbesartan; Kinetics; Losartan; Models, Biological; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles | 2001 |
Can angiotensin II receptor blockers be used in patients who have developed a cough or angioedema as a result of taking an ACE inhibitor?
Topics: Acrylates; Angioedema; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Black or African American; Clinical Trials as Topic; Cough; Female; Humans; Imidazoles; Irbesartan; Losartan; Male; Randomized Controlled Trials as Topic; Sex Factors; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2001 |
Inhibition of angiotensin II-induced facilitation of sympathetic neurotransmission in the pithed rat: a comparison between losartan, irbesartan, telmisartan, and captopril.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Captopril; Decerebrate State; Electric Stimulation; Irbesartan; Losartan; Male; Norepinephrine; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Sympathetic Nervous System; Synaptic Transmission; Telmisartan; Tetrazoles | 2001 |
Synthesis and study of a cyclic angiotensin II antagonist analogue reveals the role of pi*--pi* interactions in the C-terminal aromatic residue for agonist activity and its structure resemblance with AT(1) non-peptide antagonists.
Topics: Acrylates; Angiotensin II; Animals; Antihypertensive Agents; Biochemistry; Biphenyl Compounds; Drug Design; Imidazoles; Irbesartan; Losartan; Magnetic Resonance Spectroscopy; Male; Models, Molecular; Peptides, Cyclic; Rabbits; Structure-Activity Relationship; Tetrazoles; Thiophenes | 2001 |
Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Dose-Response Relationship, Drug; Electric Stimulation; Irbesartan; Losartan; Male; Mesenteric Arteries; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Sympathetic Nervous System; Telmisartan; Tetrazoles; Vasoconstrictor Agents | 2001 |
Different types of antagonism by losartan and irbesartan on the effects of angiotensin II and its degradation products in rabbit arteries.
Topics: Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Anti-Bacterial Agents; Antihypertensive Agents; Biphenyl Compounds; Endothelium, Vascular; Femoral Artery; Imidazoles; In Vitro Techniques; Irbesartan; Leucine; Losartan; Male; Peptides; Protease Inhibitors; Pyridines; Rabbits; Receptor, Angiotensin, Type 1; Renal Artery; Tetrazoles; Vasoconstrictor Agents | 2001 |
pK(a) determination of angiotensin II receptor antagonists (ARA II) by spectrofluorimetry.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Hydrogen-Ion Concentration; Irbesartan; Losartan; Spectrometry, Fluorescence; Tetrazoles | 2001 |
Angiotensin II receptor blockers and nephropathy trials.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypertension; Irbesartan; Kidney Failure, Chronic; Losartan; Obesity; Tetrazoles; Vasodilator Agents | 2001 |
Drug companies should not have the final say in the design of clinical trials.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Industry; Enalapril; Humans; Irbesartan; Losartan; Research Design; Tetrazoles | 2001 |
Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension, Renal; Irbesartan; Kidney; Losartan; Male; Primary Prevention; Prognosis; Tetrazoles; Treatment Outcome | 2001 |
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout.
Topics: Antihypertensive Agents; Biphenyl Compounds; Gout; Humans; Hypertension; Irbesartan; Losartan; Tetrazoles; Uric Acid | 2002 |
Preventing nephropathy in patients with type 2 diabetes.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Management; Humans; Hypertension; Irbesartan; Kidney Failure, Chronic; Losartan; Proteinuria; Tetrazoles; Treatment Outcome; United States | 2002 |
Application of capillary zone electrophoresis to the screening of some angiotensin II receptor antagonists.
Topics: Acrylates; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Chemical Fractionation; Electrophoresis, Capillary; Imidazoles; Irbesartan; Losartan; Mathematical Computing; Molecular Structure; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2002 |
Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hyperkalemia; Irbesartan; Kidney Failure, Chronic; Losartan; Tetrazoles | 2002 |
Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Irbesartan; Losartan; Oxidative Stress; Tetrazoles | 2002 |
Class benefits of AT(1) antagonists in Type 2 diabetes with nephropathy.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Irbesartan; Kidney Failure, Chronic; Losartan; Middle Aged; Receptor, Angiotensin, Type 1; Tetrazoles | 2002 |
Two angiotensin AT1 receptor antagonists, irbesartan and losartan, effects in cholesterol-fed rabbits.
Topics: Acetylcholine; Angiotensin Receptor Antagonists; Animals; Aorta, Thoracic; Biphenyl Compounds; Cholesterol; Cholesterol, Dietary; Coronary Vessels; Dose-Response Relationship, Drug; Hypercholesterolemia; In Vitro Techniques; Irbesartan; Lipoproteins, HDL; Lipoproteins, LDL; Losartan; Male; Mesenteric Arteries; Nitroprusside; Norepinephrine; Potassium Chloride; Rabbits; Receptor, Angiotensin, Type 1; Serotonin; Tetrazoles; Time Factors; Vasodilator Agents | 2002 |
A population-based European cohort study of persistence in newly diagnosed hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Calcium Channel Blockers; Cohort Studies; Europe; Female; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Receptors, Angiotensin; Retreatment; Tetrazoles; Treatment Failure | 2002 |
Sympatholytic properties of several AT1-receptor antagonists in the isolated rabbit thoracic aorta.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta, Thoracic; Benzimidazoles; Benzoates; Biphenyl Compounds; Dose-Response Relationship, Drug; Electric Stimulation; In Vitro Techniques; Irbesartan; Losartan; Norepinephrine; Osmolar Concentration; Rabbits; Receptor, Angiotensin, Type 1; Sympathetic Nervous System; Sympatholytics; Synaptic Transmission; Telmisartan; Tetrazoles | 2002 |
Irbesartan substitution for valsartan or losartan in treating hypertension.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Female; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Retrospective Studies; Tetrazoles; Therapeutic Equivalency; Valine; Valsartan | 2002 |
Control of dendritic cell differentiation by angiotensin II.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antibodies; Benzimidazoles; Biphenyl Compounds; Cell Differentiation; Cells, Cultured; Dendritic Cells; Endocytosis; Hematopoietic Stem Cells; Humans; Irbesartan; Losartan; Lymphocyte Activation; Mice; Models, Biological; Monocytes; Phenotype; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles | 2003 |
Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Binding Sites; Binding, Competitive; Biphenyl Compounds; Chemokine CCL2; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Irbesartan; Lipoproteins, LDL; Losartan; Monocytes; Platelet Activating Factor; Platelet Membrane Glycoproteins; Receptor, Angiotensin, Type 1; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Tetrazoles | 2003 |
A two-state model of antagonist-AT1 receptor interaction: further support by binding studies at low temperature.
Topics: Angiotensin Receptor Antagonists; Animals; Binding Sites; Biphenyl Compounds; CHO Cells; Cold Temperature; Computer Simulation; Cricetinae; Imidazoles; Irbesartan; Kinetics; Losartan; Models, Biological; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Recombinant Proteins; Tetrazoles; Thermodynamics; Transfection | 2003 |
Cardiology patient page. Angiotensin receptor blockers.
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Diuretics; Dizziness; Drug Combinations; Drug Interactions; Heart Failure; Humans; Hypertension; Imidazoles; Irbesartan; Kidney Diseases; Losartan; Olmesartan Medoxomil; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2003 |
Functional comparison of the antagonistic properties of some Angiotensin II type 1 receptor blockers on the contraction elicited by Angiotensin II and thromboxane A2 on human saphenous veins.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Antagonism; Humans; Imidazoles; In Vitro Techniques; Irbesartan; Losartan; Muscle Contraction; Muscle, Smooth, Vascular; Receptors, Thromboxane A2, Prostaglandin H2; Saphenous Vein; Tetrazoles; Valine; Valsartan | 2003 |
[Fast-acting sartan. High blood pressure therapy without long waiting time].
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Olmesartan Medoxomil; Rats; Tetrazoles; Time Factors; Valine; Valsartan | 2003 |
[Dosage equivalents of AT1-receptor antagonists available in Germany].
Topics: Acrylates; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Germany; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Olmesartan Medoxomil; Placebos; Telmisartan; Tetrazoles; Therapeutic Equivalency; Thiophenes; Time Factors; Valine; Valsartan | 2003 |
Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Calcium; Desoxycorticosterone; Disease Models, Animal; Endothelin A Receptor Antagonists; Humans; Hypertension; Irbesartan; Losartan; Male; Oxazoles; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptor, Endothelin A; Sodium; Sulfonamides; Tetrazoles | 2004 |
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Cell Differentiation; Cells, Cultured; Chlorocebus aethiops; Drug Evaluation, Preclinical; Gene Expression Regulation; Imidazoles; Insulin; Irbesartan; Losartan; Male; Mice; Models, Molecular; Myoblasts; Protein Conformation; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Structure-Activity Relationship; Telmisartan; Tetrazoles; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors; Triglycerides; Valine; Valsartan; Weight Gain | 2004 |
Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.
Topics: 3T3 Cells; Acrylates; Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Cell Differentiation; Genes, Reporter; Imidazoles; Insulin Resistance; Irbesartan; Losartan; Luciferases; Mice; PC12 Cells; Rats; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoid X Receptors; Telmisartan; Tetrazoles; Thiophenes; Transcription Factors; Transfection | 2004 |
Effect of high glucose on superoxide in human mesangial cells: role of angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cell Culture Techniques; Diabetic Nephropathies; Glucose; Humans; Irbesartan; Kidney Glomerulus; Losartan; Oxidants; Superoxide Dismutase; Superoxides; Tetrazoles | 2005 |
Peripheral sympatholytic actions of four AT1 antagonists: are they relevant for long-term antihypertensive efficacy?
Topics: Acrylates; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Electric Stimulation; Imidazoles; Irbesartan; Losartan; Male; Norepinephrine; Rats; Rats, Inbred SHR; Sympathetic Fibers, Postganglionic; Sympatholytics; Tetrazoles; Thiophenes; Time Factors; Treatment Outcome | 2005 |
Novel polymer monolith microextraction using a poly(methacrylic acid-ethylene glycol dimethacrylate) monolith and its application to simultaneous analysis of several angiotensin II receptor antagonists in human urine by capillary zone electrophoresis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Electrophoresis, Capillary; Ethylene Glycols; Humans; Irbesartan; Losartan; Methacrylates; Receptors, Angiotensin; Sensitivity and Specificity; Telmisartan; Tetrazoles | 2006 |
Effects of losartan and irbesartan administration on brain angiotensinogen mRNA levels.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Biphenyl Compounds; Brain; Dose-Response Relationship, Drug; Intubation, Gastrointestinal; Irbesartan; Losartan; Male; Rats; Rats, Inbred WKY; RNA, Messenger; Tetrazoles; Time Factors | 2005 |
Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation.
Topics: Adipogenesis; Adiponectin; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Humans; Irbesartan; Lipoprotein Lipase; Losartan; Luciferases; Male; Pioglitazone; PPAR gamma; Receptor, Angiotensin, Type 1; RNA, Messenger; Telmisartan; Tetrazoles; Thiazolidinediones | 2006 |
Liquid chromatographic determination of irbesartan in human plasma.
Topics: Biphenyl Compounds; Chromatography, High Pressure Liquid; Drug Stability; Ether; Freezing; Humans; Irbesartan; Losartan; Methylene Chloride; Molecular Structure; Reproducibility of Results; Sodium Hydroxide; Spectrometry, Fluorescence; Tetrazoles | 2007 |
Angiotensin II receptor blockers for the treatment of heart failure: a class effect?
Topics: Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; British Columbia; Drug Prescriptions; Female; Heart Failure; Hospital Information Systems; Humans; Irbesartan; Losartan; Male; Ontario; Proportional Hazards Models; Quebec; Retrospective Studies; Survival Analysis; Survival Rate; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cost-Benefit Analysis; Drug Costs; Humans; Hypertension; Irbesartan; Losartan; Markov Chains; Tetrazoles; Valine; Valsartan | 2008 |
Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect.
Topics: Adverse Drug Reaction Reporting Systems; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Approval; Humans; Irbesartan; Losartan; Tetrazoles; Time Factors; United States; Valine; Valsartan | 2008 |
Telmisartan and carotid intima-media thickness regression: a class effect of angiotensin-receptor blockers?
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Carotid Arteries; Humans; Irbesartan; Losartan; Telmisartan; Tetrazoles; Tunica Intima; Tunica Media; Valine; Valsartan | 2008 |
Simultaneous quantification of losartan and active metabolite in human plasma by liquid chromatography-tandem mass spectrometry using irbesartan as internal standard.
Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Calibration; Chromatography, High Pressure Liquid; Humans; Indicators and Reagents; Irbesartan; Losartan; Quality Control; Reference Standards; Reproducibility of Results; Tandem Mass Spectrometry; Tetrazoles | 2009 |
HPLC determination of irbesartan in human plasma: its application to pharmacokinetic studies.
Topics: Acetonitriles; Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Chromatography, High Pressure Liquid; Humans; Irbesartan; Losartan; Male; Reproducibility of Results; Sample Size; Sensitivity and Specificity; Spectrometry, Fluorescence; Tetrazoles; Time Factors; Young Adult | 2009 |
Angiotensin II receptor blockers in pregnancy: a report of five cases.
Topics: Abnormalities, Drug-Induced; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Female; Gestational Age; Humans; Hypertension; Infant, Newborn; Irbesartan; Kidney Diseases; Losartan; Oligohydramnios; Pregnancy; Pregnancy Complications, Cardiovascular; Premature Birth; Retrospective Studies; Risk Assessment; Slovenia; Tetrazoles | 2009 |
Hydrophilic interaction chromatography-tandem mass spectrometric analysis of irbesartan in human plasma: application to pharmacokinetic study of irbesartan.
Topics: Administration, Oral; Biphenyl Compounds; Calibration; Chromatography, Liquid; Humans; Irbesartan; Linear Models; Losartan; Male; Reference Values; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tetrazoles; Time Factors | 2009 |
Losartan counteracts the hyper-reactivity to angiotensin II and ROCK1 over-activation in aortas isolated from streptozotocin-injected diabetic rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Aorta, Thoracic; Biphenyl Compounds; Diabetes Mellitus, Experimental; In Vitro Techniques; Irbesartan; Losartan; Male; Rats; Rats, Wistar; rho-Associated Kinases; Tetrazoles; Up-Regulation; Vasoconstriction | 2009 |
Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.
Topics: Albuminuria; Amides; Biphenyl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Fumarates; Health Care Costs; Humans; Hypertension; Irbesartan; Losartan; Quality-Adjusted Life Years; Tetrazoles | 2009 |
Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes.
Topics: Adenosine Triphosphatases; Angiotensin II Type 1 Receptor Blockers; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Benzoates; Biological Transport; Biphenyl Compounds; Caco-2 Cells; Calcium Channel Blockers; Cardiotonic Agents; Cell Membrane; Digoxin; Drug Interactions; Humans; Irbesartan; Losartan; Telmisartan; Tetrazoles; Verapamil | 2010 |
Involvement of the renin-angiotensin system in the development of vascular damage in a rat model of arthritis: effect of angiotensin receptor blockers.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Arthritis, Experimental; Biphenyl Compounds; Cardiovascular Diseases; Disease Models, Animal; Endothelium, Vascular; Gene Expression; Hypertrophy; Irbesartan; Losartan; Male; Oxidative Stress; Rats; Rats, Inbred Lew; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Risk Reduction Behavior; Tetrazoles; Vasoconstrictor Agents | 2010 |
Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Benzimidazoles; Biological Transport; Biphenyl Compounds; Digoxin; Fluoresceins; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Membrane Transport Proteins; Mice; Multidrug Resistance-Associated Protein 2; Olmesartan Medoxomil; Tetrazoles; Thiophenes | 2010 |
Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Combinations; Female; Greece; Humans; Hydrochlorothiazide; Hypertension; Irbesartan; Losartan; Male; Markov Chains; Middle Aged; Models, Economic; Quality of Life; Sex Factors; Tetrazoles; Valine; Valsartan | 2011 |
A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity.
Topics: Alanine; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Chlorocebus aethiops; COS Cells; Humans; Imidazoles; Inositol Phosphates; Irbesartan; Losartan; Polymorphism, Single Nucleotide; Receptor, Angiotensin, Type 1; Telmisartan; Tetrazoles; Threonine; Valine; Valsartan | 2010 |
A small difference in the molecular structure of angiotensin II receptor blockers induces AT₁ receptor-dependent and -independent beneficial effects.
Topics: 3T3-L1 Cells; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cell Line; Cells, Cultured; Chemokine CCL2; Chlorocebus aethiops; COS Cells; Endothelium, Vascular; Fibroblasts; HEK293 Cells; Humans; Irbesartan; Kidney; Losartan; Mice; NF-kappa B; PPAR gamma; Receptor, Angiotensin, Type 1; Tetrazoles | 2010 |
Irbesartan attenuates ischemic brain damage by inhibition of MCP-1/CCR2 signaling pathway beyond AT₁ receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Brain Ischemia; Germanium; Irbesartan; Losartan; Male; Mice; Mice, Inbred C57BL; Organometallic Compounds; Propionates; Receptors, CCR2; Signal Transduction; Tetrazoles | 2011 |
Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure.
Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Confounding Factors, Epidemiologic; Electronic Health Records; Female; Heart Failure; Hospitalization; Humans; Irbesartan; Losartan; Male; Models, Structural; Proportional Hazards Models; Retrospective Studies; Risk; Tetrazoles; Treatment Outcome; United States; Valine; Valsartan | 2012 |
Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Black or African American; Blood Pressure; Diabetes Mellitus; Electronic Health Records; Female; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Obesity; Primary Health Care; Retrospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan; White People; Young Adult | 2011 |
Subtle issues in model specification and estimation of marginal structural models.
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Female; Heart Failure; Humans; Irbesartan; Losartan; Male; Tetrazoles; Valine; Valsartan | 2012 |
Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Disease Models, Animal; Epithelial-Mesenchymal Transition; Fibrosis; Heart; Hepatocyte Growth Factor; Hypertension; Hypertrophy, Left Ventricular; Irbesartan; Kidney; Losartan; Mice; Mice, Knockout; Myocardium; PPAR gamma; Receptor, Angiotensin, Type 1; Signal Transduction; Tetrazoles | 2013 |
Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardiomegaly; Catalase; Disease Models, Animal; Hypertension; Irbesartan; Losartan; Male; Myocardium; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Superoxide Dismutase; Tetrazoles; Time Factors | 2013 |
Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetic Angiopathies; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Irbesartan; Losartan; Male; Myocardial Infarction; Proportional Hazards Models; Retrospective Studies; Stroke; Telmisartan; Tetrazoles; Treatment Outcome | 2013 |
Exposure of cardiomyocytes to angiotensin II induces over-activation of monoamine oxidase type A: implications in heart failure.
Topics: Aldehyde Dehydrogenase; Angiotensin II; Animals; Biphenyl Compounds; Catalase; Enzyme Activation; Heart Failure; Hyperglycemia; Irbesartan; Losartan; Monoamine Oxidase; Myocytes, Cardiac; Rats; Tetrazoles | 2013 |
Maintaining goal blood pressures after switching from olmesartan to other angiotensin receptor blockers.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Drug Substitution; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Retrospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Cardiovascular Diseases; Cohort Studies; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Proportional Hazards Models; Registries; Retrospective Studies; Survival Rate; Taiwan; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Intermittent losartan administration triggers cardiac post-conditioning in isolated rat hearts: role of BK2 receptors.
Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Bradykinin; Cardiotonic Agents; Heart; Hemodynamics; In Vitro Techniques; Irbesartan; Ischemic Postconditioning; Losartan; Male; Mitogen-Activated Protein Kinases; Myocardial Infarction; Myocardial Reperfusion Injury; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Systole; Tetrazoles | 2014 |
Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Bilirubin; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Irbesartan; Kidney Failure, Chronic; Losartan; Male; Middle Aged; Retrospective Studies; Tetrazoles | 2014 |
Bilirubin: a potential biomarker and therapeutic target for diabetic nephropathy.
Topics: Bilirubin; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Irbesartan; Losartan; Male; Tetrazoles | 2014 |
A substrate pharmacophore for the human sodium taurocholate co-transporting polypeptide.
Topics: Angiotensin II Type 1 Receptor Blockers; Bile Acids and Salts; Biphenyl Compounds; HEK293 Cells; Humans; Irbesartan; Losartan; Organic Anion Transporters, Sodium-Dependent; Symporters; Tetrazoles | 2015 |
Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Irbesartan; Kidney Failure, Chronic; Losartan; Male; Middle Aged; Prognosis; Renin-Angiotensin System; Risk Factors; Tetrazoles | 2016 |
Effects of Uric Acid on the NO Production of HUVECs and its Restoration by Urate Lowering Agents.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzbromarone; Biphenyl Compounds; Cells, Cultured; Glucose Transport Proteins, Facilitative; Human Umbilical Vein Endothelial Cells; Humans; Irbesartan; Losartan; Monocarboxylic Acid Transporters; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphorylation; Tetrazoles; Uric Acid; Uricosuric Agents | 2016 |
The velocity of antihypertensive effects of seven angiotensin II receptor blockers determined by home blood pressure measurements.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Blood Pressure Determination; Female; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Oxadiazoles; Self Care; Telmisartan; Tetrazoles; Time Factors; Valsartan | 2016 |
Influence of initial angiotensin receptor blockers on treatment persistence in uncomplicated hypertension: A nation-wide population-based study.
Topics: Acrylates; Adult; Aged; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cohort Studies; Female; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Medication Adherence; Middle Aged; Outcome Assessment, Health Care; Republic of Korea; Retrospective Studies; Risk Factors; Tetrazoles; Thiophenes; Valsartan | 2016 |
Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus.
Topics: Adult; Albuminuria; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus, Type 2; Female; Humans; Irbesartan; Losartan; Male; Metabolome; Middle Aged; Models, Molecular; Tetrazoles | 2016 |
Protolytic Equilibria of Sartans in Micellar Solutions of Differently Charged Surfactants.
Topics: Biphenyl Compounds; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Irbesartan; Losartan; Micelles; Molecular Structure; Protons; Solubility; Solutions; Solvents; Surface-Active Agents; Tetrazoles; Valsartan; Water | 2016 |
Complex formation equilibria of Cu
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Coordination Complexes; Copper; Humans; Irbesartan; Losartan; Tetrazoles; Zinc | 2017 |
Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood-Brain Barrier; Brain Ischemia; Disease Models, Animal; Dose-Response Relationship, Drug; Irbesartan; Losartan; Male; Neuroprotective Agents; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Stroke; Tetrazoles; Tissue Distribution | 2017 |
Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population.
Topics: Adult; Asian People; Biphenyl Compounds; Blood Glucose; Carbamates; Cells, Cultured; China; Dose-Response Relationship, Drug; Drug Interactions; Genotype; Healthy Volunteers; Humans; Imidazoles; Irbesartan; Liver-Specific Organic Anion Transporter 1; Losartan; Male; Piperidines; Polymorphism, Single Nucleotide; Tetrazoles; Valsartan; Young Adult | 2018 |
Angiotensin II type 1 receptor blockers decrease kynurenic acid production in rat kidney in vitro.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Humans; Imidazoles; Irbesartan; Kidney; Kynurenic Acid; Losartan; Male; Rats, Wistar; Telmisartan; Tetrazoles; Transaminases; Valsartan | 2019 |
Hypertension Hot Potato - Anatomy of the Angiotensin-Receptor Blocker Recalls.
Topics: Angiotensin II Type 1 Receptor Blockers; Dimethylnitrosamine; Drug Contamination; Drug Recalls; Humans; Hypertension; Irbesartan; Losartan; Nitrosamines; United States; United States Food and Drug Administration; Valsartan | 2019 |
HPLC method transfer study for simultaneous determination of seven angiotensin II receptor blockers.
Topics: Acrylates; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Chlorthalidone; Chromatography, High Pressure Liquid; Hydrochlorothiazide; Imidazoles; Irbesartan; Losartan; Molecular Structure; Software; Tablets; Tetrazoles; Thiophenes; Valsartan | 2020 |
Applications of shun shell column and nanocomposite sorbent for analysis of eleven anti-hypertensive in human plasma.
Topics: Adsorption; Antihypertensive Agents; Chromatography, High Pressure Liquid; Diltiazem; Furosemide; Humans; Hydrochlorothiazide; Irbesartan; Iron; Labetalol; Limit of Detection; Losartan; Metal Nanoparticles; Methyldopa; Nanocomposites; Polyvinyl Alcohol; Prazosin; Propranolol; Reproducibility of Results; Solid Phase Microextraction; Spironolactone; Valsartan | 2020 |
Comparative analysis of the efficacy of angiotensin II receptor blockers for uric acid level change in asymptomatic hyperuricaemia.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cohort Studies; Female; Humans; Hyperuricemia; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Retrospective Studies; Tetrazoles; Time Factors; Uric Acid | 2020 |
Differential Scanning Calorimetry (DSC) on Sartan/Cyclodextrin Delivery Formulations.
Topics: Calorimetry, Differential Scanning; Cyclodextrins; Drug Carriers; Irbesartan; Losartan | 2021 |
Inhibition of the Renin-Angiotensin System Fails to Suppress β-Aminopropionitrile-Induced Thoracic Aortopathy in Mice-Brief Report.
Topics: Aminopropionitrile; Angiotensin II; Angiotensinogen; Animals; Aortic Aneurysm, Thoracic; Aortic Rupture; Dilatation, Pathologic; Disease Models, Animal; Irbesartan; Losartan; Lysine; Male; Mice; Mice, Inbred C57BL; Protein-Lysine 6-Oxidase; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System | 2022 |
Sartan blood pressure regulators in classical and biofilm wastewater treatment - Concentrations and metabolism.
Topics: Angiotensin II Type 1 Receptor Blockers; Biofilms; Blood Pressure; Humans; Irbesartan; Losartan; Sewage; Valsartan; Wastewater; Water Pollutants, Chemical; Water Purification | 2023 |
Investigation of Carcinogenic Impurities of N-Nitrosamines in Sartan Pharmaceutical Products Marketed in Brazil: Development and Validation of Method Based on High-Performance Liquid Chromatography-Tandem Mass Spectrometry.
Topics: Angiotensin II Type 1 Receptor Blockers; Brazil; Carcinogens; Chromatography, High Pressure Liquid; Humans; Irbesartan; Losartan; Nitrosamines; Pharmaceutical Preparations; Tandem Mass Spectrometry; Telmisartan; Valsartan | 2023 |
Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Canada; Cohort Studies; Denmark; Humans; Hypertension; Irbesartan; Losartan; Retrospective Studies; Tetrazoles; United Kingdom; Valsartan | 2023 |
A collaborative study of the impact of N-nitrosamines presence and ARB recall on ARB utilization - results from IQVIA™ Disease Analyzer Germany.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Germany; Humans; Hypertension; Irbesartan; Losartan; Nitrosamines; Valsartan | 2023 |
Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Cerebrovascular Disorders; Heart Failure; Humans; Irbesartan; Losartan; Myocardial Infarction; Retrospective Studies; Telmisartan; Tetrazoles; Valsartan | 2023 |